Literature DB >> 29319505

KPC-2-producing Klebsiella pneumoniae ST11 in a Children's Hospital in Poland.

Monika Machulska1, Anna Baraniak1, Iwona Żak2, Katarzyna Bojarska3, Dorota Żabicka3, Iwona Sowa-Sierant2, Waleria Hryniewicz3, Marek Gniadkowski1.   

Abstract

Four Klebsiella pneumoniae isolates from children hospitalized over 10 months in an intensive care unit in a children's teaching hospital in Poland were analyzed. All of the isolates belonged to a single pulsotype and sequence type (ST) 11, and produced the KPC-2 carbapenemase and extended-spectrum β-lactamase (ESBL) CTX-M-15. They were resistant to a variety of antimicrobials, and their β-lactam resistance patterns were typical for KPC producers. This is one of few cases of identification of KPC (or carbapenemase)-producing K. pneumoniae in a pediatric center in Poland.

Entities:  

Keywords:  KPC-2 producing K. pneumoniae ST11; carbapenemase; epidemiology

Mesh:

Substances:

Year:  2017        PMID: 29319505     DOI: 10.5604/01.3001.0010.4884

Source DB:  PubMed          Journal:  Pol J Microbiol        ISSN: 1733-1331


  3 in total

1.  Convergence of carbapenem resistance and hypervirulence in a highly-transmissible ST11 clone of K. pneumoniae: An epidemiological, genomic and functional study.

Authors:  Ping Li; Qiqiang Liang; Wugao Liu; Beiwen Zheng; Lizhang Liu; Wei Wang; Zhijiang Xu; Man Huang; Youjun Feng
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

2.  Clonal Dissemination of Multiple Carbapenemase Genes in Carbapenem-Resistant Enterobacterales Mediated by Multiple Plasmids in China.

Authors:  Jun Li; Ziyan Huang; Mengli Tang; Changhang Min; Fengjun Xia; Yongmei Hu; Haichen Wang; Haijian Zhou; Mingxiang Zou
Journal:  Infect Drug Resist       Date:  2021-08-19       Impact factor: 4.003

3.  First report of Klebsiella quasipneumoniae harboring bla KPC-2 in Saudi Arabia.

Authors:  Sharif Hala; Chakkiath Paul Antony; Mohammed Alshehri; Abdulhakeem O Althaqafi; Asim Alsaedi; Areej Mufti; Mai Kaaki; Baraa T Alhaj-Hussein; Hosam M Zowawi; Abdulfattah Al-Amri; Arnab Pain
Journal:  Antimicrob Resist Infect Control       Date:  2019-12-19       Impact factor: 4.887

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.